News Image

Looking for growth without the hefty price tag? Consider NASDAQ:EXEL.

By Mill Chart

Last update: Nov 6, 2023

Take a closer look at EXELIXIS INC (NASDAQ:EXEL), an affordable growth stock uncovered by our stock screener. NASDAQ:EXEL boasts strong growth prospects and excels in financial health indicators, all while maintaining a reasonable valuation. Let's break it down further.

A Closer Look at Growth for NASDAQ:EXEL

ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:EXEL was assigned a score of 7 for growth:

  • Looking at the last year, EXEL shows a quite strong growth in Revenue. The Revenue has grown by 10.25% in the last year.
  • The Revenue has been growing by 28.91% on average over the past years. This is a very strong growth!
  • Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 33.60% on average per year.
  • EXEL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.53% yearly.
  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

Valuation Examination for NASDAQ:EXEL

To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:EXEL has achieved a 6 out of 10:

  • Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 94.54% of the companies are valued more expensively.
  • EXEL's Price/Forward Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 96.69% of the companies in the same industry.
  • 94.70% of the companies in the same industry are more expensive than EXEL, based on the Enterprise Value to EBITDA ratio.
  • EXEL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EXEL is cheaper than 97.02% of the companies in the same industry.
  • EXEL has a very decent profitability rating, which may justify a higher PE ratio.
  • EXEL's earnings are expected to grow with 28.74% in the coming years. This may justify a more expensive valuation.

Assessing Health Metrics for NASDAQ:EXEL

ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:EXEL, the assigned 7 for health provides valuable insights:

  • An Altman-Z score of 7.70 indicates that EXEL is not in any danger for bankruptcy at the moment.
  • EXEL has a Altman-Z score of 7.70. This is amongst the best in the industry. EXEL outperforms 85.60% of its industry peers.
  • EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • EXEL has a Current Ratio of 4.68. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 4.60 indicates that EXEL has no problem at all paying its short term obligations.

Understanding NASDAQ:EXEL's Profitability

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:EXEL, the assigned 7 is a significant indicator of profitability:

  • With an excellent Return On Assets value of 5.23%, EXEL belongs to the best of the industry, outperforming 95.03% of the companies in the same industry.
  • The Return On Equity of EXEL (6.50%) is better than 94.70% of its industry peers.
  • EXEL's Return On Invested Capital of 3.94% is amongst the best of the industry. EXEL outperforms 95.53% of its industry peers.
  • EXEL has a Profit Margin of 9.58%. This is amongst the best in the industry. EXEL outperforms 95.36% of its industry peers.
  • EXEL has a better Operating Margin (8.24%) than 95.36% of its industry peers.
  • EXEL's Gross Margin of 96.31% is amongst the best of the industry. EXEL outperforms 96.52% of its industry peers.

More Affordable Growth stocks can be found in our Affordable Growth screener.

Check the latest full fundamental report of EXEL for a complete fundamental analysis.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

EXELIXIS INC

NASDAQ:EXEL (6/2/2025, 8:00:02 PM)

After market: 43 +0.12 (+0.28%)

42.88

-0.16 (-0.37%)



Find more stocks in the Stock Screener

EXEL Latest News and Analysis

ChartMill News Image8 days ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors

EXELIXIS INC (NASDAQ:EXEL) shows strong earnings growth, expanding margins, and solid cash flow, making it a standout for growth investors following Louis Navellier’s strategy.

ChartMill News Image12 days ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation

EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.

ChartMill News Image14 days ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) – An Undervalued Biotech Stock with Strong Fundamentals

EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.

ChartMill News Image17 days ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in High Growth Momentum and Minervini’s Trend Template

EXELIXIS INC (NASDAQ:EXEL) meets Minervini’s Trend Template with strong technicals and high growth momentum, making it a standout in biotech. Review its full technical and fundamental strengths before considering an investment.

Follow ChartMill for more